LIVE INFLUENZA VACCINE FOR CHILDREN AND ADULTS: TRANSMISSIBILITY IN CHILDREN 3-6 YEARS OF AGE


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences, St. Petersburg Live attenuated influenza vaccines (LAIV) are used in Russia to immunize all population groups, including children. The immunogenicity, acceptance, and transmissibility of the components of commercially available trivalent LAIV vaccine in vaccinated children aged 3 to 6 years were studied. Vaccine viruses were isolated from nasal swabs of the vaccinees, using chicken embryos and MDCK cells. The use of a combination of these two culture systems produced the best effect in isolating vaccine viruses. Examination of placebo group children who were in constant contact with the vaccinated subjects showed that LAIV strains had not been transmitted from the vaccinated to unvaccinated children. The acceptance of vaccine virus correlated well with its immunogenicity.

全文:

受限制的访问

作者简介

N. LARIONOVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: nvlarionova@mail.ru
St. Petersburg

I. KISELEVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

E. GRIGORIEVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

I. ISAKOVA-SIVAK

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

S. DONINA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

L. RUDENKO

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

St. Petersburg

参考

  1. Александрова Г.И., Климов А.И. Живая вакцина против гриппа. СПб: Наука, 1994.
  2. Klimov A.I., Kiseleva I.V., Desheva J.A. et al. Live attenuated reassortant influenza vaccine prepared usingA/Leningrad/134/17/57 (H2N2) donor strain is genetically stable after replication in children 3-6 years of age In: Proceedings of options for the control of influenza IV. Hersonissos, Crete, Greece. 23-28 September 2000. Amsterdam: Elsever Sciense, 2001: 951-954.
  3. van Voorthuizen F., Jens D., Saes F. Characterization and clinical evaluation of live influenza A vaccine prepared from a recombinant of the A/USSR/92/77 (H1N1) and the cold adapted A/Ann Arbor/6/60 (H2N2) strains. Antivir. Res. 1981; 1: 107-122.
  4. Vesikari T., Karvonen A., Korhonen T. et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Ped. Inf. Dis. J. 2006; 25 (7): 590-595.
  5. Иванова В.Т., Бурцева Е.И., Слепушкин А.Н. и др. Характеристика штаммов вируса гриппа А(Н3N2) в эпидемическом сезоне 2003-2004 гг. в России. Вопр. вирусол. 2006; 1: 19-23.
  6. Litvinova O., Konovalova N., Lobova T. The etiological surveillance for influenza in Russia during the seasons 1993— 2003. International Congress Series 1263. 2004: 295-298.
  7. Демидова С.А., Гадашевич В.Н., Кириллова Ф.М. и др. Выделение и изучение вирусов гриппа А на разных клеточных культурах. Вопр. вирусол. 1979; 4: 346-350.
  8. Davies H.W., Appleyard G., Cunningham P. et al. The use of a continuous cell line for the isolation of influenza viruses. Bull. WHO 1978; 56: 991-993.
  9. Инструкция по применению вакцины гриппозной аллантоисной интраназальной живой сухой. Утверждена Главным санитарным врачом РФ Г.Г. Онищенко 16 июня 2004 г.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##